首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >Stains Modulate Oxidized Low-Density Lipoprotein-Mediated Adhesion Molecule Expression in Human Coronary Artery Endothelial Cells: Role of LOX-1
【24h】

Stains Modulate Oxidized Low-Density Lipoprotein-Mediated Adhesion Molecule Expression in Human Coronary Artery Endothelial Cells: Role of LOX-1

机译:污渍调节人冠状动脉内皮细胞中氧化的低密度脂蛋白介导的粘附分子表达:LOX-1的作用。

获取原文
获取原文并翻译 | 示例
           

摘要

LOX-1, a receptor for oxidized low-density lipoprotein (ox-LDL), plays a critical role in endothelialdysfunction and atherosclerosis. LOX-1 activation also plays an important role in monocyte adhesion to endothelial cells. A number of studies show that 3-hydroxy-3-methylglutary coenzyme A reductase inhibitors (statins) reduce total LDL cholesterol and exert a cardioprotective effect. We examined the modulation of LOX-1 expression and its function by two different statins, simvastatin and atorvastatin, in human coronary artery endothelial cells (HCAECs). We observed that ox-LDL (40 mug/ml) treatment up-regulated the expression of E-and P-selectins, VCAM-1 and ICAM-1 in HCAECs. Ox-LDL mediated these effects via LOX-1, since antisense to LOX-1 mRNA decreased LOX-1 expression and subsequent adhesion molecule expression. Pretreatment of HCAECs with simvastatin or atorvastatin (1 and 10 muM) reduced ox-LDL-induced expression of LOX-1 as well as adhesion molecules (all P < 0.05). A high concentration of statins (10 muM) was more potent than the low concentration (1 muM) (P < 0.05). Both statins reduced ox-LDL-mediated activation of the redox-sensitive nuclear factor-kappaB (NF-kappaB) but not AP-1. These observations indicate that LOX-1 activation plays an important role in ox-LDL-induced expression of adheison molecules. Inhibition of expression of LOX-1 and adhesion molecules and activation of NF-kappaB may be another mechanism of beneficial effects of statins in vascular diseases.
机译:LOX-1是氧化型低密度脂蛋白(ox-LDL)的受体,在内皮功能障碍和动脉粥样硬化中起关键作用。 LOX-1激活在单核细胞粘附于内皮细胞中也起着重要作用。大量研究表明,3-羟基-3-甲基谷氨酸辅酶A还原酶抑制剂(他汀类药物)可降低总LDL胆固醇并发挥心脏保护作用。我们研究了两种不同的他汀类药物辛伐他汀和阿托伐他汀在人冠状动脉内皮细胞(HCAEC)中对LOX-1表达的调节及其功能。我们观察到,ox-LDL(40杯/毫升)处理可上调HCAECs中E和P选择素,VCAM-1和ICAM-1的表达。 Ox-LDL通过LOX-1介导了这些作用,因为对LOX-1 mRNA的反义降低了LOX-1表达和随后的粘附分子表达。用辛伐他汀或阿托伐他汀(1和10μM)预处理HCAECs会降低ox-LDL诱导的LOX-1和粘附分子的表达(所有P <0.05)。高浓度的他汀类药物(10μM)比低浓度的他汀类药物(1μM)更有效(P <0.05)。两种他汀类药物均能减少ox-LDL介导的对氧化还原敏感的核因子-kappaB(NF-kappaB)的激活,但不会降低AP-1。这些观察结果表明LOX-1激活在ox-LDL诱导的粘附分子表达中起重要作用。抑制LOX-1和粘附分子的表达以及激活NF-κB可能是他汀类药物在血管疾病中有益作用的另一种机制。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号